Major Players in Drug Eluting Stents Market Focus on R&D of New Generation of Everolimus-Eluting Coronary Stents

 

High prevalence of cardiovascular diseases is expected to propel growth of the global drug eluting stents market. According to the American Heart Association's Heart and Stroke Statistics 2019 Update, around 48% of all adults in the U.S. suffered from some type of cardiovascular disease in 2016.

A drug eluting stent is a catheterized or peripheral arterial stenosis implanted into a diseased or narrowed peripheral or coronary artery that efficiently releases a medication to block arterial cell proliferation. This prevents the clotted arterial artery from being blocked by arterial fibroids. The treatment with this stent prevents the arteries from having to be cut or carved open because the catheter is designed to bypass the heart muscle and allow it to deliver medications directly to the diseased or narrowed artery. The most common types of such stents are used for patients with persistent constricted atherosclerosis in the coronary arteries. They have also been successfully used to treat embolism, a condition where a blood clot forms in a blocked artery.

Drug eluting stents can be used to treat various different diseases and conditions. These stents effectively reverse the effects of coronary artery disease by removing fatty deposits from within the walls of the artery, reducing blood flow to the heart and forcing it to work harder at pumping blood around the body. Other uses for such devices are for reducing cholesterol levels in high blood pressure, controlling high blood pressure and controlling irregular heartbeat rhythms.

Approval and launch of new devices is also expected to propel growth of the global drug eluting stents market. In May 2018, Abbott Laboratories received the U.S. FDA approval for XIENCE Sierra, the new generation of everolimus-eluting coronary stent. XIENCE received approval from the Japan’s regulatory body in April 2018.

Major players in the global drug eluting stents market are also focused on R&D of new products. In July 2019, SINOMED completed enrollment in the PIONEER III randomized, controlled clinical trial to assess the safety and effectiveness of the BuMA Supreme DES in order to obtain key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System. Similarly, in November 2019, Boston Scientific announced positive data for Eluvia Drug-Eluting Vascular Stent for the treatment of femoropopliteal disease.

North America drug eluting stents market is wintering several approval and launches. In February 2019, Biotronik SE & Co. KG received the U.S. Food and Drug Administration’s approval for its drug-eluting stent system for the treatment of patients with coronary artery disease. The DES is used during PCI and elutes sirolimus through a bioabsorbable polymer coating.